Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease

Hypertension

Volumn 54, Issue 3, 2009, Pages

  Dhaun, Neeraj ^a   MacIntyre, Iain M ^a   Melville, Vanessa ^a   Lilitkarntakul, Pajaree ^a   Johnston, Neil R ^a   Goddard, Jane ^b   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR; ANTIHYPERTENSIVE AGENT; CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE;

CHRONIC KIDNEY DISEASE; DISEASE SEVERITY; FOCAL GLOMERULOSCLEROSIS; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HEART RATE; NOTE; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEART RATE; HUMANS; KIDNEY FAILURE, CHRONIC; PEPTIDES, CYCLIC; PROTEINURIA; RECEPTORS, ENDOTHELIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 70349241843     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.138263     Document Type: Letter

References (5)

1. Benigni A, Remuzzi G. Treatment of chronic proteinuric kidney disease: What next? Hypertension. 2009;54:29-31.
2. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension. 2009;54:113-119.
3. Rump LC. Secondary rise of albuminuria under AT1-receptor blockade-what is the potential role of aldosterone escape? Nephrol Dial Transplant. 2007;22:5-8.
4. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
5. Dhaun N, Macintyre IM, Bellamy CO, Kluth DC. Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney. Am J Kidney Dis. 2009; Epub ahead of print April 17, 2009.